Comparison of nephrotoxicity between 30-minute intravenous drip and intravenous bolus of colistin: randomized control trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20240910005

Enrollment

196

Registered

2024-09-10

Start date

2023-12-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrotoxicity in a patient who receives colistin for treatment of MDR infectious disease. colistin, colistimethate, nephrotoxicity, infusion, administration

Interventions

Receive intravenous CMS intravenous administration within 3 minutes.,Receive intravenous CMS intravenous administration within 30 minutes.

Experimental Drug,Active Comparator Drug

Intervention arm,Control arm

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age more than 18-year-old on the date of recruitment 2. Had a clinical indication for intravenous colistin 3. Receive intravenous colistin less than 48 hours before a recruitment

Exclusion criteria

Exclusion criteria: 1. patient who receives renal replacement therapy before colistin administration 2. patient who developed AKI before colistin administration

Design outcomes

Primary

Measure	Time frame
Acute kidney injury During CMS administration and after discontinuation 24 hours Serum creatinine, Urine output	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactPornpan Koomanachai

Faculty of Medicine Siriraj Hospital

nokmed@yahoo.com0819066545

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026